BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17460607)

  • 1. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.
    Ieiri I; Suwannakul S; Maeda K; Uchimaru H; Hashimoto K; Kimura M; Fujino H; Hirano M; Kusuhara H; Irie S; Higuchi S; Sugiyama Y
    Clin Pharmacol Ther; 2007 Nov; 82(5):541-7. PubMed ID: 17460607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
    Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
    Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans.
    Oh ES; Kim CO; Cho SK; Park MS; Chung JY
    Drug Metab Pharmacokinet; 2013; 28(3):196-202. PubMed ID: 23007012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin.
    Choi CI; Lee YJ; Lee HI; Kim BH; Kim MJ; Jang CG; Bae JW; Lee SY
    Xenobiotica; 2012 May; 42(5):496-501. PubMed ID: 22077103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers.
    Wen J; Xiong Y
    J Clin Pharm Ther; 2010 Feb; 35(1):99-104. PubMed ID: 20175818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.
    Chung JY; Cho JY; Yu KS; Kim JR; Oh DS; Jung HR; Lim KS; Moon KH; Shin SG; Jang IJ
    Clin Pharmacol Ther; 2005 Oct; 78(4):342-50. PubMed ID: 16198653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.
    Hua WJ; Hua WX; Fang HJ
    Cardiovasc Ther; 2012 Oct; 30(5):e234-41. PubMed ID: 21884024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
    Zhou Q; Ruan ZR; Jiang B; Yuan H; Zeng S
    Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.
    Karibe T; Hagihara-Nakagomi R; Abe K; Imaoka T; Mikkaichi T; Yasuda S; Hirouchi M; Watanabe N; Okudaira N; Izumi T
    Pharm Res; 2015 May; 32(5):1634-47. PubMed ID: 25380981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
    Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
    Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.
    Deng JW; Song IS; Shin HJ; Yeo CW; Cho DY; Shon JH; Shin JG
    Pharmacogenet Genomics; 2008 May; 18(5):424-33. PubMed ID: 18408565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
    Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
    Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.
    Keskitalo JE; Pasanen MK; Neuvonen PJ; Niemi M
    Pharmacogenomics; 2009 Oct; 10(10):1617-24. PubMed ID: 19842935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
    Ieiri I; Higuchi S; Sugiyama Y
    Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
    Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y
    Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan.
    Kim CO; Cho SK; Oh ES; Park MS; Chung JY
    J Cardiovasc Pharmacol; 2012 Jul; 60(1):49-54. PubMed ID: 22494992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
    Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
    Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin.
    Hu M; Mak VW; Yin OQ; Chu TT; Tomlinson B
    Drug Metab Pharmacokinet; 2013; 28(2):104-8. PubMed ID: 22850760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.
    Li R; Barton HA
    Clin Pharmacokinet; 2018 Apr; 57(4):491-503. PubMed ID: 28653144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase.
    Fujino H; Saito T; Ogawa S; Kojima J
    J Pharm Pharmacol; 2005 Oct; 57(10):1305-11. PubMed ID: 16259759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.